+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Saudi Arabia Vaccine Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)

  • PDF Icon

    Report

  • 250 Pages
  • June 2025
  • Region: Saudi Arabia
  • Expert Market Research
  • ID: 6100908
The Saudi Arabia vaccine market was valued at USD 1.14 Billion in 2024, driven by the government initiatives, strategic partnerships, and advancements in healthcare infrastructure in the region. The market is anticipated to grow at a CAGR of 4.90% during the forecast period of 2025-2034, with the values likely to reach USD 1.84 Billion by 2034.

Saudi Arabia Vaccine Market Overview

The vaccine market in Saudi Arabia is experiencing steady growth, driven by strong government support, advancement in healthcare infrastructure, and increasing public awareness of preventive care. The country is taking significant steps to localize vaccine production, reduce dependency on imports, and position itself as a regional hub for vaccine manufacturing and distribution. Moreover, as part of its Vision 2030 initiative, the Saudi government has prioritized healthcare transformation and pharmaceutical self-sufficiency, which is projected to boost market growth in the forecast period.

Saudi Arabia Vaccine Market Growth Drivers

Strategic Investments in Vaccine Production Facilities to Drive Market Growth

Saudi Arabia is making strategic investments in vaccine production facilities as part of a national effort to improve pharmaceutical self-sufficiency. For instance, in 2023, the Saudi Authority for Industrial Cities and Technology Zones (MODON) signed a SAR 500 million (USD 133 million) investment agreement with the Vaccine Industrial Company to establish a joint venture vaccine manufacturing facility in Sudair City for Industry and Business. Such initiatives are anticipated to drive market growth in the coming years.

Saudi Arabia Vaccine Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Focus on Domestic Vaccine Manufacturing Capabilities to Boost Market Growth

In March 2022, it was reported that the Saudi Arabian government would invest USD 3.4 billion in the vaccine and biomedical drugs sector as part of a strategic initiative to reduce reliance on imports and strengthen domestic manufacturing capabilities. This substantial investment reflects the country’s pharmaceutical market trend toward vaccine localization, self-sufficiency, and global competitiveness, which is projected to support the vaccine market expansion in the region.

Integration of Vision 2030 with Healthcare Transformation Set to Elevate Saudi Arabia Vaccine Market Value

Under Vision 2030, Saudi Arabia has identified life sciences and biotechnology as key growth sectors. The vaccine industry is now a strategic priority, receiving targeted support through funding, policy reforms, and infrastructure development. This ensures a sustained pipeline of investment and innovation in vaccine production and public health programs, which is poised to positively impact the market dynamics.

Saudi Arabia Vaccine Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type

  • Multivalent Vaccines
  • Monovalent Vaccines

Market Breakup by Type

  • Subunit Vaccines
  • Recombinant vaccines
  • Conjugate Vaccines
  • Toxoid vaccines
  • Inactivated
  • Live Attenuated
  • mRNA vaccines
  • Viral vector vaccines

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Nasal

Market Breakup by Disease Indication

  • Viral Diseases
  • Hepatitis
  • Influenza
  • HPV
  • MMR
  • Rotavirus
  • Herpes Zoster
  • COVID-19
  • Others
  • Bacterial Vaccines
  • Meningococcal Diseases
  • Pneumococcal diseases
  • DPT
  • Others
  • Cancer Vaccines
  • Allergy Vaccines

Market Breakup by Age

  • Pediatric
  • Adult

Market Breakup by End User

  • Hospital Pharmacies
  • Retail Pharmacies
  • Government Suppliers
  • Others

Saudi Arabia Vaccine Market Share

Segmentation Based on Product Type to Witness Substantial Growth

Based on the product type, the market is segmented into multivalent and monovalent vaccines. Multivalent vaccines protect against multiple strains or types of a pathogen in one shot, making them more efficient and cost-effective for national immunization programs. These vaccines are widely used in Saudi Arabia’s routine childhood vaccination schedule, contributing significantly to their market dominance. Moreover, the country's Ministry of Health favors multivalent vaccines in its bulk purchasing and public immunization campaigns to maximize coverage and efficiency.

Saudi Arabia Vaccine Market Analysis by Region

The vaccine market in Saudi Arabia varies across regions due to differences in population, healthcare infrastructure, and local needs. The Central Region, especially Riyadh, is the center of government and healthcare planning and holds a substantial market share. Many vaccine policies and programs are managed from here, and the region has well-developed medical facilities and logistics networks. The Western Region, which includes Jeddah, Makkah, and Madinah, is also a major contributor to the vaccine market. These cities are densely populated and attract millions of pilgrims each year. As a result, there is a high demand for travel and seasonal vaccines, especially for diseases like meningitis and influenza.

Leading Players in the Saudi Arabia Vaccine Market

The key features of the market report comprise patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

GlaxoSmithKline plc

GSK plays a significant role in expanding global vaccine access, especially for diseases like HPV, meningitis, influenza, and hepatitis. It is active in public-private partnerships and global immunization initiatives, which are relevant for emerging markets like Saudi Arabia. GSK’s experience in technology transfer and local partnerships can help Saudi Arabia enhance its domestic production capabilities as it seeks to localize vaccine manufacturing under Vision 2030.

Merck & Co.

Merck is a key player in vaccines for diseases such as HPV (Gardasil), measles, mumps, rubella (MMR), and Ebola. Its investment in R&D and global clinical trials drives innovation across the sector. In Saudi Arabia, Merck’s advanced vaccines and commitment to global access align with the Kingdom’s goals of improving public health outcomes and introducing next-generation vaccines into the regional market.

Sanofi

Sanofi, headquartered in France, is a leading vaccine producer through its vaccine division, Sanofi Pasteur, offering immunizations for influenza, polio, rabies, and yellow fever, among others. The company is highly active in emerging markets, including Saudi Arabia, often working with governments and health organizations to increase vaccine coverage.

Pfizer Inc

Pfizer Inc. is a global pharmaceutical leader, known for co-developing the first approved mRNA COVID-19 vaccine in partnership with BioNTech. The company has demonstrated a strong commitment to partnering with governments on public health initiatives, and its engagement in Saudi Arabia through supply agreements or prospective local manufacturing plays a key role in strengthening the country’s vaccine security and supporting the growth of its vaccine market.

Other key players in the market include AstraZeneca plc, Johnson & Johnson Services, Inc., and CSL Behring.

Key Questions Answered in the Saudi Arabia Vaccine Market Report

  • What was the Saudi Arabia vaccine market value in 2024?
  • What is the Saudi Arabia vaccine market forecast outlook for 2025-2034?
  • What is the market segmentation based on product type?
  • What is the market segmentation based on type?
  • What is the market breakup based on the route of administration?
  • What is the market breakup by disease indication?
  • What is the market breakup by age?
  • What is the market breakup by end user?
  • What major factors aid the Saudi Arabia vaccine market demand?
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the major drivers, opportunities, and restraints in the market?
  • What are the major trends influencing the market?
  • Who are the key players involved in the Saudi Arabia vaccine market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Vaccine Market Overview
3.1 Middle East and Africa Vaccine Market Overview
3.1.1 Middle East and Africa Vaccine Market Historical Value (2018-2024)
3.1.2 Middle East and Africa Vaccine Market Forecast Value (2025-2034)
3.2 Saudi Arabia Vaccine Market Overview
3.2.1 Saudi Arabia Vaccine Market Historical Value (2018-2024)
3.2.2 Saudi Arabia Vaccine Market Forecast Value (2025-2034)
4 Saudi Arabia Vaccine Market Landscape*
4.1 Saudi Arabia Vaccine Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Saudi Arabia Vaccine Market: Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Type
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by Disease Indication
4.2.5 Analysis by Age
5 Saudi Arabia Vaccine Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 PESTEL Analysis
5.3.1 Political
5.3.2 Economic
5.3.3 Social
5.3.4 Technological
5.3.5 Legal
5.3.6 Environment
5.4 Porter’s Five Forces Model
5.4.1 Bargaining Power of Suppliers
5.4.2 Bargaining Power of Buyers
5.4.3 Threat of New Entrants
5.4.4 Threat of Substitutes
5.4.5 Degree of Rivalry
5.5 Key Demand Indicators
5.6 Key Price Indicators
5.7 Industry Events, Initiatives, and Trends
5.8 Value Chain Analysis
6 Saudi Arabia Vaccine Market Segmentation (218-2034)
6.1 Saudi Arabia Vaccine Market (2018-2034) by Product Type
6.1.1 Market Overview
6.1.2 Multivalent Vaccines
6.1.3 Monovalent Vaccines
6.2 Saudi Arabia Vaccine Market (2018-2034) by Type
6.2.1 Market Overview
6.2.2 Subunit Vaccines
6.2.2.1 Recombinant vaccines
6.2.2.2 Conjugate Vaccines
6.2.2.3 Toxoid vaccines
6.2.3 Inactivated
6.2.4 Live Attenuated
6.2.5 mRNA vaccines
6.2.6 Viral vector vaccines
6.3 Saudi Arabia Vaccine Market (2018-2034) by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parenteral
6.3.4 Nasal
6.4 Saudi Arabia Vaccine Market (2018-2034) by Disease Indication
6.4.1 Market Overview
6.4.2 Viral Diseases
6.4.2.1 Hepatitis
6.4.2.2 Influenza
6.4.2.3 HPV
6.4.2.4 MMR
6.4.2.5 Rotavirus
6.4.2.6 Herpes Zoster
6.4.2.7 COVID-19
6.4.2.8 Others
6.4.3 Bacterial Vaccines
6.4.3.1 Meningococcal Diseases
6.4.3.2 Pneumococcal diseases
6.4.3.3 DPT
6.4.3.4 Others
6.4.4 Cancer Vaccines
6.4.5 Allergy Vaccines
6.5 Saudi Arabia Vaccine Market (2018-2034) by Age
6.5.1 Market Overview
6.5.2 Pediatric
6.5.3 Adult
6.6 Saudi Arabia Vaccine Market (2018-2034) by End User
6.6.1 Market Overview
6.6.2 Hospital Pharmacies
6.6.3 Retail Pharmacies
6.6.4 Government Suppliers
6.6.5 Others
7 Regulatory Framework
8 Patent Analysis
8.1 Analysis By Drug Type of Patent
8.2 Analysis by Publication Year
8.3 Analysis by Issuing Authority
8.4 Analysis by Patent Age
8.5 Analysis by CPC Analysis
8.6 Analysis by Patent Valuation
8.7 Analysis by Key Players
9 Clinical Trials Analysis
9.1 Analysis by Trial Registration Year
9.2 Analysis by Trial Status
9.3 Analysis by Trial Phase
9.4 Analysis by Therapeutic Area
9.5 Analysis by Geography
10 Funding and Investment Analysis
10.1 Analysis by Funding Instances
10.2 Analysis by Drug Class of Funding
10.3 Analysis by Funding Amount
10.4 Analysis by Leading Players
10.5 Analysis by Leading Investors
10.6 Analysis by Geography
11 Strategic Initiatives
11.1 Analysis by Partnership Instances
11.2 Analysis by Drug Class of Partnership
11.3 Analysis by Leading Players
11.4 Analysis by Geography
12 Supplier Landscape
12.1 GlaxoSmithKline plc
12.1.1 Financial Analysis
12.1.2 Product Portfolio
12.1.3 Demographic Reach and Achievements
12.1.4 Company News and Development
12.1.5 Certifications
12.2 Merck & Co.
12.2.1 Financial Analysis
12.2.2 Product Portfolio
12.2.3 Demographic Reach and Achievements
12.2.4 Company News and Development
12.2.5 Certifications
12.3 Sanofi
12.3.1 Financial Analysis
12.3.2 Product Portfolio
12.3.3 Demographic Reach and Achievements
12.3.4 Company News and Development
12.3.5 Certifications
12.4 Pfizer Inc.
12.4.1 Financial Analysis
12.4.2 Product Portfolio
12.4.3 Demographic Reach and Achievements
12.4.4 Company News and Development
12.4.5 Certifications
12.5 AstraZeneca plc
12.5.1 Financial Analysis
12.5.2 Product Portfolio
12.5.3 Demographic Reach and Achievements
12.5.4 Company News and Development
12.5.5 Certifications
12.6 Johnson & Johnson Services, Inc.
12.6.1 Financial Analysis
12.6.2 Product Portfolio
12.6.3 Demographic Reach and Achievements
12.6.4 Company News and Development
12.6.5 Certifications
12.7 CSL Behring
12.7.1 Financial Analysis
12.7.2 Product Portfolio
12.7.3 Demographic Reach and Achievements
12.7.4 Company News and Development
12.7.5 Certifications
13 Saudi Arabia Vaccine Market - Distribution Model (Additional Insight)
13.1 Overview
13.2 Potential Distributors
13.3 Key Parameters for Distribution Partner Assessment
14 Key Opinion Leaders (KOL) Insights (Additional Insight)

Companies Mentioned

  • GlaxoSmithKline plc
  • Merck & Co.
  • Sanofi
  • Pfizer Inc.

Table Information